{"id":"W4206959584","doi":"10.1016/s0140-6736(22)00010-1","title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","year":2022,"lang":"en","type":"article","venue":"The Lancet","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":686,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"National Institute for Health and Care Research; Roche","keywords":"Macular degeneration; Clinical trial; Phase (matter); Phases of clinical research; Degeneration (medical)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004671772,0.002009562,0.003849296,0.0005701776,0.000632525,0.00154935,0.00113156,0.00324816,0.00379325],"category_scores_gemma":[0.003354066,0.001003334,0.004125765,0.0005916108,0.00157173,0.001800206,0.000513221,0.003221386,0.0008747906],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001118109,"about_ca_system_score_gemma":0.0009120504,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00148419,"about_ca_topic_score_gemma":0.002970178,"domain_scores_codex":[0.9983752,0.0008004591,0.0001247733,0.0002800807,0.0001321206,0.0002874047],"domain_scores_gemma":[0.9978835,0.0007964883,0.0005310573,0.000228148,0.0001254562,0.000435371],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9745589,0.002483894,0.0006242648,0.0007191146,0.001841793,0.00003570339,0.0000839038,0.0001738711,0.002585705,0.00008731724,0.0003870543,0.0164184],"study_design_scores_gemma":[0.9551497,0.03989389,0.002670882,0.00005258041,0.001126626,0.00005274007,0.00002267368,0.0001340927,0.0002969758,0.0001822708,0.00039282,0.00002473153],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9719782,0.0219282,0.0007181527,0.0007074109,0.000504219,0.001366208,0.0008412731,0.00008706807,0.001869158],"genre_scores_gemma":[0.9845961,0.00697767,0.001335967,0.001263455,0.0005727703,0.001813868,0.001057019,0.00002663046,0.00235644],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004671772,"threshold_uncertainty_score":0.02470696,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04564152384848981,"score_gpt":0.3562724226406661,"score_spread":0.3106308987921763,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}